Shahrokh F. Shariat

Active 1996–2026

Also published as
Shahrokh F Shariat · Shahrokh F. SHARIAT
804
Papers
79,350
Citations
148
h-index
729
i10-index

Citations

Citations per year for Shahrokh F. Shariat1979: 1 citations1985: 2 citations1992: 2 citations1997: 2 citations1998: 1 citations1999: 11 citations2000: 9 citations2001: 27 citations2002: 25 citations2003: 48 citations2004: 64 citations2005: 95 citations2006: 119 citations2007: 148 citations2008: 166 citations2009: 229 citations2010: 277 citations2011: 432 citations2012: 453 citations2013: 405 citations2014: 386 citations2015: 367 citations2016: 383 citations2017: 365 citations2018: 366 citations2019: 1,927 citations2020: 2,450 citations2021: 2,307 citations2022: 1,799 citations2023: 1,475 citations2024: 2,757 citations2025: 1,227 citations2026: 48 citations1980–1984: no citations, so these years are not shown1986–1991: no citations, so these years are not shown1993–1996: no citations, so these years are not shown

Citation sources

Countries

World map of the countries and regions citing this authorUnited States: 3,919 citing papers, 19.2% of this breakdownChina: 2,066 citing papers, 10.1% of this breakdownItaly: 1,634 citing papers, 8% of this breakdownGermany: 1,354 citing papers, 6.6% of this breakdownUnited Kingdom: 1,086 citing papers, 5.3% of this breakdownCanada: 955 citing papers, 4.7% of this breakdownFrance: 886 citing papers, 4.3% of this breakdownNetherlands: 751 citing papers, 3.7% of this breakdownAustria: 746 citing papers, 3.6% of this breakdownJapan: 655 citing papers, 3.2% of this breakdownSpain: 618 citing papers, 3% of this breakdownSwitzerland: 430 citing papers, 2.1% of this breakdown
0%19.2%Other 26.2%

Fields

  • Medicine81.8%
  • Biochemistry, Genetics and Molecular Biology12.7%
  • Immunology and Microbiology1.4%
  • Computer Science1%
  • Engineering0.9%
  • Health Professions0.6%
  • Other1.6%

Topics

  • Bladder and Urothelial Cancer Treatments14.5%
  • Urinary and Genital Oncology Studies7.1%
  • Prostate Cancer Diagnosis and Treatment6.5%
  • Prostate Cancer Treatment and Research6%
  • Renal cell carcinoma treatment3.5%
  • Cancer Immunotherapy and Biomarkers2.4%
  • Other60%

Coauthors

All papers

Open in search
  1. European Association of Urology Guidelines on Non–muscle-invasive Bladder Cancer (Ta, T1, and Carcinoma in Situ)

    Authors: , , , , , , , , , , , , , , , , - European Urology 2021 cited by 1,623

  2. Adjuvant Nivolumab versus Placebo in Muscle-Invasive Urothelial Carcinoma

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , - New England Journal of Medicine 2021 cited by 1,031

  3. Bladder cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up

    Authors: , , , , , , , , , , , , - Annals of Oncology 2021 cited by 525

  4. European Association of Urology Guidelines on Upper Urinary Tract Urothelial Carcinoma: 2023 Update

    Authors: , , , , , , , , , , , , , , , , , , , - European Urology 2023 cited by 503

  5. Epidemiology and Risk Factors of Urothelial Bladder Cancer

    Authors: , , , , , , , , , , - European Urology 2012 cited by 2,187

  6. European Association of Urology (EAU) Prognostic Factor Risk Groups for Non–muscle-invasive Bladder Cancer (NMIBC) Incorporating the WHO 2004/2016 and WHO 1973 Classification Systems for Grade: An Update from the EAU NMIBC Guidelines Panel

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Andrea Haitel, Jean‐François Côté, Soha El Sheikh, Luca Lunelli, Ferrán Algaba, Isabel Alemany, Francesco Soria, Willemien Runneboom, Johannes Breyer, Jakko A. Nieuwenhuijzen, Carlos Llorente, Luca Molinaro, Christina A. Hulsbergen‐van de Kaa, Matthias Evert, Lambertus A. Kiemeney, James N’Dow, Karin Plass, Otakar Čapoun, Viktor Soukup, José L. Domínguez-Escrig, Daniel L. Cohen, Joan Palou, Paolo Gontero, Maximilian Burger, Richard Zigeuner, Amir Hugh Mostafid, Shahrokh F. Shariat, Morgan Rouprêt, Éva Compérat, Marko Babjuk, Bas W.G. van Rhijn - European Urology 2021 cited by 463

  7. European Association of Urology Guidelines on Non-muscle-invasive Bladder Cancer (TaT1 and Carcinoma In Situ) - 2019 Update

    Authors: , , , , , , , , , , , , , , , , , - European Urology 2019 cited by 1,327

  8. European Association of Urology Guidelines on Upper Urinary Tract Urothelial Carcinoma: 2020 Update

    Authors: , , , , , , , , , , , , , , , , , - European Urology 2020 cited by 941

  9. Prevalence and Trends in Kidney Stone Among Adults in the USA: Analyses of National Health and Nutrition Examination Survey 2007–2018 Data

    Authors: , , , , , , , , , , , - European Urology Focus 2020 cited by 295

  10. EAU Guidelines on Non–Muscle-invasive Urothelial Carcinoma of the Bladder: Update 2016

    Authors: , , , , , , , , , , , , , , - European Urology 2016 cited by 2,298

  11. Global Trends of Bladder Cancer Incidence and Mortality, and Their Associations with Tobacco Use and Gross Domestic Product Per Capita

    Authors: , , , , , , , , , , , , - European Urology 2020 cited by 262

  12. ESMO Clinical Practice Guideline interim update on first-line therapy in advanced urothelial carcinoma

    Authors: , , , , , , , , , , , , - Annals of Oncology 2024 cited by 159

  13. Gender and Bladder Cancer: A Collaborative Review of Etiology, Biology, and Outcomes

    Authors: , , , , , , , , - European Urology 2015 cited by 683

  14. European Association of Urology Guidelines on Upper Urinary Tract Urothelial Cell Carcinoma: 2015 Update

    Authors: , , , , , , , , , , , - European Urology 2015 cited by 1,344

  15. Epidemiology, diagnosis, preoperative evaluation and prognostic assessment of upper-tract urothelial carcinoma (UTUC)

    Authors: , , , , , , , , , , , , , , - World Journal of Urology 2016 cited by 472

  16. Repeat Transurethral Resection in Non–muscle-invasive Bladder Cancer: A Systematic Review

    Authors: , , , , , , , , - European Urology 2018 cited by 332

  17. Outcomes of radical nephroureterectomy: A series from the Upper Tract Urothelial Carcinoma Collaboration

    Authors: , , , , , , , , , - Cancer 2009 cited by 1,134

  18. Recurrence mechanisms of non-muscle-invasive bladder cancer — a clinical perspective

    Authors: , , , , , - Nature Reviews Urology 2022 cited by 196

  19. Supervised machine learning enables non-invasive lesion characterization in primary prostate cancer with [68Ga]Ga-PSMA-11 PET/MRI

    Authors: , , , , , , , , , , , , , , , , , , , , , , , - European Journal of Nuclear Medicine and Molecular Imaging 2020 cited by 141

  20. Prevalence and trends in urinary incontinence among women in the United States, 2005–2018

    Authors: , , , , , , , , , - American Journal of Obstetrics and Gynecology 2021 cited by 257

  21. Androgen Receptor Signaling Inhibitors in Addition to Docetaxel with Androgen Deprivation Therapy for Metastatic Hormone-sensitive Prostate Cancer: A Systematic Review and Meta-analysis

    Authors: , , , , , , , , , , , , , , , , - European Urology 2022 cited by 107

  22. What Is the Significance of Variant Histology in Urothelial Carcinoma?

    Authors: , , , , , , , , , , , - European Urology Focus 2019 cited by 244

  23. Diagnostic Accuracy of Novel Urinary Biomarker Tests in Non–muscle-invasive Bladder Cancer: A Systematic Review and Network Meta-analysis

    Authors: , , , , , , , , , , , , , , , , , , , , , - European Urology Oncology 2021 cited by 112

  24. Distribution of metastatic sites in renal cell carcinoma: a population-based analysis

    Authors: , , , , , , , , , , , , - Annals of Oncology 2011 cited by 658